Publication in Vaccines Highlights Important Benefits of PharmaJet® Tropis® Intradermal Vaccination over Intramuscular Standard of Care

• Substantial Improvements in Coverage of IPV2. Vaccine coverage of the second dose of inactivated polio vaccine (IPV2) administered with Tropis ID increased by 11.2% compared to the standard of care (SoC, full dose delivered by needle and syringe intramuscular delivery). On a relative basis, the odds of receiving 2 doses of IPV are doubled when using Tropis ID.
• Preferred by Vast Majority of Healthcare Workers. Needle-free Tropis ID was the preferred method of vaccination for routine immunization (RI) as reported by 97% of healthcare workers surveyed, who cited that, compared to the SoC, Tropis ID was (i) easier to use (95%), and (ii) children experienced less discomfort (94%).
• Significant Cost Reductions. Incremental savings with needle-free could range from US$0.07 to US$1.00 per dose, with up to 47% total immunization cost savings compared to the SoC in a full-scale scenario. This equates to a potential savings of ~US$50 million over a 5-year period using Tropis ID for the Nigeria immunization program.

GOLDEN, Colo. — June 5, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An implementation hybrid trial.¹ The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months. This study is the first to measure coverage benefits of Tropis ID in RI settings, adding to the evidence of the value of needle-free intradermal delivery in the global pursuit of polio eradication. While Nigeria improved full regimen coverage from 33% in 2016 to 57% in 2022,² it is actively pursuing new approaches that may bring further improvements to coverage and reduce costs as the country prepares for transition from Gavi support,³ while navigating funding reductions in global health programs. Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in high-risk polio environments, with over 12 million injections administered to date.⁴ The Vaccines publication highlighted that when compared to the SoC, Tropis ID demonstrated:

• Increased coverage: IPV2 coverage was 11.2% higher. On a relative basis, this means the odds of receiving 2 doses of IPV are doubled when Tropis ID is used.
• Cost savings: Up to 47% total immunization costs savings can be realized when using Tropis ID for IPV delivery,⁴ which equates to a potential savings for the Nigeria immunization program of ~US$50 million over a 5-year period.
• Acceptability: 97% of healthcare workers preferred Tropis ID for routine immunization, noting it is easy to operate, associated with less perceived discomfort by children during administration, and elicited a positive caregiver response.

“This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio,” said Paul LaBarre, Vice President Global Business Development, PharmaJet. “With the added benefits of intradermal dose sparing and the associated cost savings, Tropis ID is an ideal immunization tool. We look forward to collaborating with other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs.”

Refer to Instructions for Use to ensure safe injections and to review risks.

¹ Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An implementation hybrid trial , Vaccines,16 May 2025, 13(5), p.533 ² 2023: A Critical Year for polio eradication efforts in northern Nigeria. Global Polio Eradication Initiative. 2023. (accessed on 21 March 2025) ³ Presentation of Evidence by the Polio Disease Working Group. Presented at the meeting of the Nigerian Immunization Technical Advisory Group, Abuja, Nigeria, 24 July 2018. ⁴ Data on file About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit https://www.pharmajet.com or contact PharmaJet here. Follow us on LinkedIn. About The Global Polio Eradication Strategy (GPEI) In 1988, the Global Polio Eradication Initiative (GPEI) was launched after a resolution passed by the World Health Assembly, with over 350,000 children recorded as having paralytic polio across 125 countries. The GPEI’s goals are to detect and stop the spread of poliovirus and strengthen immunization programs globally. Post-eradication strategies, such as sustaining high vaccination rates and strengthening surveillance efforts, are important in the goal of eradicating polio. The GPEI Polio Eradication Strategy 2022–2026 set 2023 as a target year to interrupt all remaining type 1 wild poliovirus (WPV1) transmission (Goal One) and type 2 circulating vaccine-derived poliovirus (cVDPV) transmission (Goal Two), with the aim of reaching eradication by 2026.